SG10202100792XA - Non-human animals having a humanized cluster of differentiation 274 gene - Google Patents

Non-human animals having a humanized cluster of differentiation 274 gene

Info

Publication number
SG10202100792XA
SG10202100792XA SG10202100792XA SG10202100792XA SG10202100792XA SG 10202100792X A SG10202100792X A SG 10202100792XA SG 10202100792X A SG10202100792X A SG 10202100792XA SG 10202100792X A SG10202100792X A SG 10202100792XA SG 10202100792X A SG10202100792X A SG 10202100792XA
Authority
SG
Singapore
Prior art keywords
differentiation
gene
human animals
humanized
cluster
Prior art date
Application number
SG10202100792XA
Other languages
English (en)
Inventor
Elena Burova
Yajun Tang
Ka-Man Venus Lai
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10202100792XA publication Critical patent/SG10202100792XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10202100792XA 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene SG10202100792XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
SG10202100792XA true SG10202100792XA (en) 2021-03-30

Family

ID=55024286

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202100792XA SG10202100792XA (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene
SG11201703931QA SG11201703931QA (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201703931QA SG11201703931QA (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Country Status (23)

Country Link
US (3) US9913461B2 (fr)
EP (2) EP3230320B1 (fr)
JP (3) JP2018500896A (fr)
KR (2) KR102316842B1 (fr)
CN (2) CN107257624B (fr)
AU (2) AU2015360667B2 (fr)
BR (1) BR112017011982A2 (fr)
CA (1) CA2968675C (fr)
CY (1) CY1123723T1 (fr)
DK (1) DK3230320T3 (fr)
ES (1) ES2841353T3 (fr)
HR (1) HRP20202034T1 (fr)
HU (1) HUE052606T2 (fr)
IL (3) IL282649B (fr)
LT (1) LT3230320T (fr)
MX (1) MX2017007636A (fr)
PT (1) PT3230320T (fr)
RS (1) RS61218B1 (fr)
RU (1) RU2711729C2 (fr)
SG (2) SG10202100792XA (fr)
SI (1) SI3230320T1 (fr)
WO (1) WO2016094481A1 (fr)
ZA (1) ZA201703263B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3230320B1 (fr) * 2014-12-09 2020-10-07 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un cluster humanisé pour le gène du cluster de différenciation cd274
MX2018005389A (es) 2015-11-20 2018-09-05 Regeneron Pharma Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
SG11201806176PA (en) 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
DK3476865T3 (da) 2016-06-28 2023-12-18 Biocytogen Pharmaceuticals Beijing Co Ltd Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (fr) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec un tigit humain ou chimérique
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041118A1 (fr) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec pd-l1 humain ou chimérique
MX2019006448A (es) 2016-12-01 2020-02-05 Regeneron Pharma Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet.
WO2019072241A1 (fr) * 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec pd-1 humain ou chimérique
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
CN116420679A (zh) 2018-03-26 2023-07-14 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
CN116200426A (zh) 2018-07-16 2023-06-02 瑞泽恩制药公司 Ditra疾病的非人动物模型及其用途
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
US20210380978A1 (en) * 2018-10-15 2021-12-09 The Brigham And Women`S Hospital, Inc. The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
CN114621971A (zh) * 2021-02-19 2022-06-14 百奥赛图(北京)医药科技股份有限公司 经遗传修饰的非人动物及其构建方法和应用
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
NZ522844A (en) 2000-06-28 2005-02-25 Brigham & Womens Hospital PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP3287144A1 (fr) * 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Compositions immunostimulantes
US20060179501A1 (en) * 2002-12-16 2006-08-10 Chan Andrew C Transgenic mice expressing human cd20
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
ES2364335T3 (es) 2003-12-24 2011-08-31 G2 Inflammation Pty Ltd Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado.
US8071839B2 (en) 2003-12-24 2011-12-06 G2 Inflammation Pty Ltd Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
JP5252922B2 (ja) 2004-10-19 2013-07-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝的改変についてホモ接合性の動物を生み出すための方法
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1997887B1 (fr) 2006-03-03 2013-09-04 Ono Pharmaceutical Co., Ltd. Multimere de domaine extracellulaire d'une molecule fonctionnelle de surface cellulaire
CN108484767B (zh) 2008-09-26 2022-01-14 达纳-法伯癌症研究公司 人抗pd-1、pd-l1和pd-l2的抗体及其应用
CA2739902A1 (fr) 2008-10-08 2010-04-15 Intrexon Corporation Cellules modifiees exprimant des immuno-modulateurs multiples et leurs utilisations
DK2379727T3 (en) * 2008-12-18 2017-01-16 Univ Erasmus Med Ct Rotterdam NON-HUMAN TRANSGENE ANIMALS EXPRESSING HUMANIZED ANTIBODIES AND USE THEREOF
EP3192811A1 (fr) 2009-02-09 2017-07-19 Université d'Aix-Marseille Anticorps pd-1 et pd-l1 et leurs utilisations
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011020014A1 (fr) 2009-08-14 2011-02-17 Regeneron Pharmaceuticals, Inc. Cassette à auto-suppression dépendant de la différenciation régulée par un promoteur
IN2012DN01769A (fr) * 2009-08-28 2015-06-05 Vlst Corp
ES2591107T3 (es) 2009-10-06 2016-11-24 Regeneron Pharmaceuticals, Inc. Ratones modificados genéticamente e injerto
WO2011060357A2 (fr) 2009-11-16 2011-05-19 The Ohio State University Cellules xénogéniques modifiées pour la réparation d'un tissu biologique
KR101934071B1 (ko) * 2009-11-24 2019-01-02 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
RU2549695C2 (ru) * 2009-12-21 2015-04-27 Ридженерон Фармасьютикалз, Инк. ГУМАНИЗИРОВАННЫЕ FCγR МЫШИ
US8507663B2 (en) * 2010-04-06 2013-08-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
KR102061143B1 (ko) 2011-02-15 2019-12-31 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
PT2770821T (pt) * 2011-10-28 2017-12-18 Regeneron Pharma Ratinhos de complexo principal de histocompatibilidade principal modificados geneticamente
WO2013078230A1 (fr) 2011-11-23 2013-05-30 The Trustees Of The University Of Pennsylvania Utilisation de cellules exprimant pdl1 pour convertir des lymphocytes t en lymphocytes t régulateurs
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
EP2890715B1 (fr) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
PL3470432T3 (pl) * 2012-08-21 2022-02-07 Sanofi Biotechnology Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
CN113897398A (zh) 2012-09-07 2022-01-07 再生元制药公司 经遗传修饰的非人动物及其使用方法
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
BR112015019950B1 (pt) 2013-02-20 2023-02-14 Regeneron Pharmaceuticals, Inc Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro
CN105164153B (zh) * 2013-02-20 2020-04-24 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
LT2958937T (lt) * 2013-02-22 2018-11-26 Regeneron Pharmaceuticals, Inc. Pelė, ekspresuojanti humanizuotą audinių dermės kompleksą
HUE040575T2 (hu) * 2013-04-16 2019-03-28 Regeneron Pharma A patkány genom célzott módosítása
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
WO2014197369A1 (fr) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions et procédés d'identification, d'évaluation, de prévention et de traitement du cancer en utilisant des isoformes pd-l1
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EP3683238A1 (fr) * 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Animaux non humains présentant un gène 1 humanisé de la mort cellulaire programmée
EP3230320B1 (fr) * 2014-12-09 2020-10-07 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un cluster humanisé pour le gène du cluster de différenciation cd274
WO2018041118A1 (fr) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec pd-l1 humain ou chimérique

Also Published As

Publication number Publication date
US20160157469A1 (en) 2016-06-09
ES2841353T3 (es) 2021-07-08
JP2018500896A (ja) 2018-01-18
KR20210130251A (ko) 2021-10-29
ZA201703263B (en) 2023-02-22
SG11201703931QA (en) 2017-06-29
WO2016094481A1 (fr) 2016-06-16
IL282649A (en) 2021-06-30
RU2017123754A (ru) 2019-01-10
KR102457921B1 (ko) 2022-10-25
KR20170101910A (ko) 2017-09-06
US9913461B2 (en) 2018-03-13
CN107257624A (zh) 2017-10-17
AU2015360667A1 (en) 2017-06-08
CN113412818B (zh) 2022-11-04
LT3230320T (lt) 2021-01-11
RU2017123754A3 (fr) 2019-06-24
US20210105983A1 (en) 2021-04-15
IL275864B (en) 2021-05-31
MX2017007636A (es) 2018-03-28
CN113412818A (zh) 2021-09-21
RS61218B1 (sr) 2021-01-29
EP3230320A1 (fr) 2017-10-18
AU2021286369A1 (en) 2022-01-20
AU2015360667B2 (en) 2021-09-23
JP2022184973A (ja) 2022-12-13
JP7488861B2 (ja) 2024-05-22
JP2021003130A (ja) 2021-01-14
CA2968675C (fr) 2023-10-17
IL282649B (en) 2022-07-01
SI3230320T1 (sl) 2021-02-26
US20180160663A1 (en) 2018-06-14
JP7145920B2 (ja) 2022-10-03
HRP20202034T1 (hr) 2021-02-19
IL275864A (en) 2020-08-31
PT3230320T (pt) 2021-01-08
IL252695B (en) 2020-07-30
DK3230320T3 (da) 2021-01-11
RU2711729C2 (ru) 2020-01-21
CY1123723T1 (el) 2022-03-24
US10881086B2 (en) 2021-01-05
KR102316842B1 (ko) 2021-10-25
HUE052606T2 (hu) 2021-05-28
EP3808775A1 (fr) 2021-04-21
EP3230320B1 (fr) 2020-10-07
CA2968675A1 (fr) 2016-06-16
CN107257624B (zh) 2021-07-13
IL252695A0 (en) 2017-08-31
BR112017011982A2 (pt) 2018-01-16
EP3808775B1 (fr) 2024-04-17

Similar Documents

Publication Publication Date Title
IL286403A (en) Non-human animals possess a humanized cluster of differentiation 47 gene
IL282649A (en) Non-human animals with a humanized gene for differentiation cluster 274
IL287519B1 (en) Non-human animals with a humanized programmed cell death gene 1
HK1253683A1 (zh) 具有人源化淋巴細胞活化基因3的非人動物